Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers

被引:15
作者
Grassi, Tommaso [1 ]
Dell'Orto, Federica [1 ]
Jaconi, Marta [2 ]
Lamanna, Maria [1 ]
De Ponti, Elena [3 ]
Paderno, Mariachiara [4 ]
Landoni, Fabio [5 ]
Leone, Biagio Eugenio [6 ]
Fruscio, Robert [5 ]
Buda, Alessandro [1 ]
机构
[1] Hosp San Gerardo, Obstet & Gynecol, I-20900 Monza, Lombardia, Italy
[2] Hosp San Gerardo, Pathol, Monza, Lombardia, Italy
[3] Hosp San Gerardo, Phys Med, Monza, Lombardia, Italy
[4] Hosp San Gerardo, Gynecol, Monza, Lombardia, Italy
[5] Univ Milano Bicocca, Obstet & Gynecol, Milan, Lombardia, Italy
[6] Univ Milano Bicocca, Pathol, Milan, Lombardia, Italy
关键词
sentinel lymph node; cervical cancer; endometrial neoplasms; SENTINEL; MELANOMA; RECOMMENDATIONS; MULTICENTER; CARCINOMA; BIOPSY; TRIAL; RISK;
D O I
10.1136/ijgc-2020-001298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To date, there is no universal consensus on which is the optimal ultrastaging protocol for sentinel lymph node (SLN) evaluation in gynecologic malignancies. To estimate the impact of different ultrastaging methods of SLNs on the detection of patients with nodal metastases in early-stage cervical and endometrial cancers and to describe the incidence of low-volume metastases between two ultrastaging protocols. Methods We retrospectively compared two ultrastaging protocols (ultrastaging-A vs ultrastaging-B) in patients with clinical stage I endometrial cancer or FIGO stage IA-IB1 cervical cancer who underwent primary surgery including SLN biopsy from October 2010 to December 2017 in our institution. The histologic subtypes and grades of the tumors were evaluated according to WHO criteria. Only SLNs underwent ultrastaging, while other lymph nodes were sectioned and examined by routine hematoxylin and eosin (H&E). Results Overall 224 patients were reviewed (159 endometrial cancer and 65 cervical cancer). Lymph node involvement was noted in 15% of patients with endometrial cancer (24/159): 24% of patients (9/38) with the ultrastaging protocol A and 12% (15/121) with the ultrastaging protocol B (p=0.08); while for cervical cancer, SLN metastasis was detected in 14% of patients (9/65): 22% (4/18) in ultrastaging-A and 11% (5/47) in ultrastaging-B (p=0.20). Overall, macrometastasis and low-volume metastases were 50% and 50% for endometrial cancer and 78% and 22% for cervical cancer. Median size of nodal metastasis was 2 (range 0.9-8.5) mm for the ultrastaging-A and 1.2 (range 0.4-2.6) mm for the ultrastaging-B protocol in endometrial cancer (p=0.25); 4 (range 2.5-9.8) mm for ultrastaging-A and 4.4 (range 0.3-7.8) mm for ultrastaging-B protocol in cervical cancer (p=0.64). Conclusion In endometrial or cervical cancer patients, the incidence of SLN metastasis was not different between the two different types of ultrastaging protocol.
引用
收藏
页码:1404 / 1410
页数:7
相关论文
共 29 条
  • [1] The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center
    Abu-Rustum, Nadeem R.
    Alektiar, Kaled
    Iasonos, Alexia
    Lev, Gali
    Sonoda, Yukio
    Aghajanian, Carol
    Chi, Dennis S.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 714 - 718
  • [2] [Anonymous], CERV CANC VERS 4 201
  • [3] [Anonymous], UT NEOPL VERS 3 2019
  • [4] Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells
    Bogani, Giorgio
    Mariani, Andrea
    Paolini, Biagio
    Ditto, Antonino
    Raspagliesi, Francesco
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 670 - 675
  • [5] Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer 99mTc and/or Blue Dye
    Buda, Alessandro
    Crivellaro, Cinzia
    Elisei, Federica
    Di Martino, Giampaolo
    Guerra, Luca
    De Ponti, Elena
    Cuzzocrea, Marco
    Giuliani, Daniela
    Sina, Federica
    Magni, Sonia
    Landoni, Claudio
    Milani, Rodolfo
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (07) : 2183 - 2191
  • [6] Burke WM, 2014, GYNECOL ONCOL, V134, P385, DOI 10.1016/j.ygyno.2014.05.018
  • [7] Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer
    Cibula, D.
    Zikan, M.
    Slama, J.
    Fischerova, D.
    Kocian, R.
    Germanova, A.
    Burgetova, A.
    Dusek, L.
    Dundr, P.
    Gregova, M.
    Nemejcova, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 83 - 86
  • [8] A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)
    Cibula, David
    Dusek, Ladislav
    Jarkovsky, J.
    Dundr, P.
    Querleu, D.
    van der Zee, A.
    Kucukmetin, A.
    Kocian, R.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (01) : 212 - 215
  • [9] Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions
    Cibula, David
    McCluggage, W. Glenn
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 152 (01) : 202 - 207
  • [10] Histopathologic Evaluation of the Sentinel Lymph Node for Malignant Melanoma: The Unstandardized Process
    Cole, Christine M.
    Ferringer, Tammie
    [J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2014, 36 (01) : 80 - 87